241 related articles for article (PubMed ID: 34673903)
1. Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis.
Hamadani M; Gopal AK; Pasquini M; Kim S; Qiu X; Ahmed S; Lazaryan A; Bhatt VR; Daly A; Lulla P; Ciurea S; Gauthier J; Agrawal V; Grover NS; Lekakis L; Modi D; Dahi PB; Herr MM; Johnson PC; Hashmi H; Hematti P; Locke FL
Blood Adv; 2022 Jan; 6(2):486-494. PubMed ID: 34673903
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation.
Fenske TS; Ahn KW; Graff TM; DiGilio A; Bashir Q; Kamble RT; Ayala E; Bacher U; Brammer JE; Cairo M; Chen A; Chen YB; Chhabra S; D'Souza A; Farooq U; Freytes C; Ganguly S; Hertzberg M; Inwards D; Jaglowski S; Kharfan-Dabaja MA; Lazarus HM; Nathan S; Pawarode A; Perales MA; Reddy N; Seo S; Sureda A; Smith SM; Hamadani M
Br J Haematol; 2016 Jul; 174(2):235-48. PubMed ID: 26989808
[TBL] [Abstract][Full Text] [Related]
3. Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission.
Shadman M; Pasquini M; Ahn KW; Chen Y; Turtle CJ; Hematti P; Cohen JB; Khimani F; Ganguly S; Merryman RW; Yared JA; Locke FL; Ahmed N; Munshi PN; Beitinjaneh A; Reagan PM; Herrera AF; Sauter CS; Kharfan-Dabaja MA; Hamadani M
Blood; 2022 Mar; 139(9):1330-1339. PubMed ID: 34570879
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.
Zurko J; Ramdial J; Shadman M; Ahmed S; Szabo A; Iovino L; Tomas AA; Sauter C; Perales MA; Shah NN; Acharya UH; Jacobson C; Soiffer RJ; Wang T; Komanduri KV; Jaglowski S; Kittai AS; Denlinger N; Iqbal M; Kharfan-Dabaja MA; Ayala E; Chavez J; Jain M; Locke FL; Samara Y; Budde LE; Mei MG; Pia AD; Feldman T; Ahmed N; Jacobs R; Ghosh N; Dholaria B; Oluwole OO; Hess B; Hassan A; Kenkre VP; Reagan P; Awan F; Nieto Y; Hamadani M; Herrera AF
Haematologica; 2023 Jan; 108(1):98-109. PubMed ID: 35833303
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Survivors after Failure of Chimeric Antigen Receptor T Cell Therapy for Large B Cell Lymphoma: A Role for Allogeneic Hematopoietic Cell Transplantation? A German Lymphoma Alliance and German Registry for Stem Cell Transplantation Analysis.
Derigs P; Bethge WA; Krämer I; Holtick U; von Tresckow B; Ayuk F; Penack O; Vucinic V; von Bonin M; Baldus C; Mougiakakos D; Wulf G; Schnetzke U; Stelljes M; Fante M; Schroers R; Kroeger N; Dreger P;
Transplant Cell Ther; 2023 Dec; 29(12):750-756. PubMed ID: 37709204
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Vital Status, Cause of Death, and Follow-Up after Hematopoietic Cell Transplantation in Linked Center for International Blood and Marrow Transplant Research and California Cancer Registry Data, 1991 to 2018.
Valcarcel B; Schonfeld SJ; Meyer CL; Brunson A; Cooley JJP; Abrahão R; Wun T; Auletta JJ; Gadalla SM; Engels E; Albert PS; Spellman SR; Rizzo JD; Shaw BE; Muffly L; Keegan THM; Morton LM
Transplant Cell Ther; 2024 Feb; 30(2):239.e1-239.e11. PubMed ID: 37981238
[TBL] [Abstract][Full Text] [Related]
7. Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?
Shah NN; Ahn KW; Litovich C; He Y; Sauter C; Fenske TS; Hamadani M
Blood; 2021 Mar; 137(10):1416-1423. PubMed ID: 33120429
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Doraiswamy A; Shah MR; Bannerji R
Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
[TBL] [Abstract][Full Text] [Related]
9. Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation.
Epperla N; Ahn KW; Khanal M; Litovich C; Ahmed S; Ghosh N; Fenske TS; Kharfan-Dabaja MA; Sureda A; Hamadani M
Transplant Cell Ther; 2021 Jan; 27(1):58-66. PubMed ID: 32956819
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation.
Jagadeesh D; Majhail NS; He Y; Ahn KW; Litovich C; Ahmed S; Aljurf M; Bacher U; Badawy SM; Bejanyan N; Cairo M; Cerny J; Epperla N; Farhadfar N; Freytes CO; Gale RP; Haverkos B; Hossain N; Inwards D; Kamble RT; Kenkre VP; Lazarus HM; Lazaryan A; Lekakis L; Mei M; Murthy HS; Mussetti A; Nathan S; Nishihori T; Olsson RF; Ramakrishnan Geethakumari P; Savani BN; Yared JA; Fenske TS; Kharfan-Dabaja MA; Sureda A; Hamadani M
Cancer; 2020 May; 126(10):2279-2287. PubMed ID: 32049359
[TBL] [Abstract][Full Text] [Related]
11. Long-term Outcomes After Hematopoietic Cell Transplant in Peripheral T-Cell Lymphoma - The Oregon Health and Science University Experience.
Galligan D; Williamson S; Myers J; Chen AI; Hayes-Lattin B; Okada C; Spurgeon S; Maziarz R; Schachter L
Clin Lymphoma Myeloma Leuk; 2023 Dec; 23(12):874-881. PubMed ID: 37741763
[TBL] [Abstract][Full Text] [Related]
12. Outcome of Allogeneic and Autologous Hematopoietic Cell Transplantation for High-Risk Peripheral T Cell Lymphomas: A Retrospective Analysis From a Chinese Center.
Huang H; Jiang Y; Wang Q; Guo L; Jin Z; Fu Z; Han Y; Sun A; Liu W; Ruan J; Wu D
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1393-1397. PubMed ID: 28478121
[TBL] [Abstract][Full Text] [Related]
13. Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL.
Jeyakumar N; Smith M
Front Immunol; 2022; 13():887866. PubMed ID: 35663947
[TBL] [Abstract][Full Text] [Related]
14. Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome.
Herrera AF; Ahn KW; Litovich C; Chen Y; Assal A; Bashir Q; Bayer RL; Coleman M; DeFilipp Z; Farhadfar N; Greenwood M; Hahn T; Horwitz M; Jacobson C; Jaglowski S; Lachance S; Langston A; Mattar B; Maziarz RT; McGuirk J; Mian MAH; Nathan S; Phillips A; Rakszawski K; Sengeloev H; Shenoy S; Stuart R; Sauter CS; Kharfan-Dabaja MA; Hamadani M
Blood Adv; 2021 Sep; 5(18):3528-3539. PubMed ID: 34496026
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of chimeric antigen receptor T cell therapy and autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma: A systematic review.
Tian L; Li C; Sun J; Zhai Y; Wang J; Liu S; Jiang Y; Wu W; Xing D; Lv Y; Guo J; Xu H; Sun H; Li Y; Li L; Zhao Z
Front Immunol; 2022; 13():1041177. PubMed ID: 36733398
[TBL] [Abstract][Full Text] [Related]
16. Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation.
Epperla N; Badar T; Szabo A; Vaughn J; Borson S; Saini NY; Patel RD; Shah NN; Hamadani M; Ahmed S; Cashen AF; Fenske TS
Blood Adv; 2019 Jun; 3(11):1661-1669. PubMed ID: 31167818
[TBL] [Abstract][Full Text] [Related]
17. Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
Schubert ML; Dietrich S; Stilgenbauer S; Schmitt A; Pavel P; Kunz A; Bondong A; Wegner M; Stadtherr P; Jung S; Ho AD; Müller-Tidow C; Schmitt M; Dreger P
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1575-1580. PubMed ID: 32422254
[TBL] [Abstract][Full Text] [Related]
18. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR.
Lazarus HM; Zhang MJ; Carreras J; Hayes-Lattin BM; Ataergin AS; Bitran JD; Bolwell BJ; Freytes CO; Gale RP; Goldstein SC; Hale GA; Inwards DJ; Klumpp TR; Marks DI; Maziarz RT; McCarthy PL; Pavlovsky S; Rizzo JD; Shea TC; Schouten HC; Slavin S; Winter JN; van Besien K; Vose JM; Hari PN
Biol Blood Marrow Transplant; 2010 Jan; 16(1):35-45. PubMed ID: 20053330
[TBL] [Abstract][Full Text] [Related]
19. Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma.
Rogers AM; Brammer JE
Curr Hematol Malig Rep; 2020 Aug; 15(4):316-332. PubMed ID: 32529515
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma.
Myers RM; Hill BT; Shaw BE; Kim S; Millard HR; Battiwalla M; Majhail NS; Buchbinder D; Lazarus HM; Savani BN; Flowers MED; D'Souza A; Ehrhardt MJ; Langston A; Yared JA; Hayashi RJ; Daly A; Olsson RF; Inamoto Y; Malone AK; DeFilipp Z; Margossian SP; Warwick AB; Jaglowski S; Beitinjaneh A; Fung H; Kasow KA; Marks DI; Reynolds J; Stockerl-Goldstein K; Wirk B; Wood WA; Hamadani M; Satwani P
Cancer; 2018 Feb; 124(4):816-825. PubMed ID: 29125192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
